GlaxoSmithKline

19 November 2024

19 Nov 2024

Primary endpoint met with a statistically significant improvement in itch over 24 weeks compared with placebo

Statement: GSK continues to show strong leadership in its Access to Medicines Index ranking

19 Nov 2024

GSK is pleased to rank 2nd in the Access to Medicine Index (ATMI) in its ninth wave.

Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC)

19 Nov 2024

Primary endpoint met with a statistically significant improvement in itch over 24 weeks compared with placebo

14 November 2024

14 Nov 2024

Full data to be presented at 2024 American Society of Hematology Annual Meeting in December.

Blenrep shows overall survival benefit in head-to-head DREAMM-7 phase III trial for relapsed/refractory multiple myeloma

14 Nov 2024

Full data to be presented at 2024 American Society of Hematology Annual Meeting in December.

13 November 2024

14 Nov 2024

New data shows potential for sequential therapy of bepirovirsen after daplusiran/tomligisiran to further increase functional cure rates.

GSK highlights key data from hepatology portfolio at the AASLD’s The Liver Meeting® 2024, emphasising patient impact in areas of high unmet need

14 Nov 2024

New data shows potential for sequential therapy of bepirovirsen after daplusiran/tomligisiran to further increase functional cure rates.

12 November 2024

12 Nov 2024

GSK’s Your Cancer Is Our Challenge will raise awareness of barriers and inspire future solutions to address them, beyond treatment.

New GSK-sponsored survey reveals unique gaps in care and support facing patients with gynaecologic cancers

12 Nov 2024

GSK’s Your Cancer Is Our Challenge will raise awareness of barriers and inspire future solutions to address them, beyond treatment.

30 October 2024

30 Oct 2024

Q3 2024 performance highlights